Technology enhancement offers fast CRISPR DNA editing with fewer off-target effects
Piscataway, New Jersey , September 20, 2016 (Newswire.com) - GenScript, the number one global provider of gene synthesis services, announced today the launch of its most versatile CRISPR service – synthetic CRISPR RNAs (crRNA). This new addition complements the company's already extensive CRISPR service and product portfolio.
“Until now, CRISPR constructs have been DNA-based, carrying a risk of insertional mutagenesis, off-target effects, and toxic delivery into stem cells and primary cells,” said GenScript’s CRISPR Services Product Manager, Laura Geuss, Ph.D. “By working immediately after delivery into the cell, our synthetic CRISPR ribonucleoproteins result in quick DNA editing and rapid cell clearance with fewer off-target risks. GenScript’s CRISPR RNAs will expand gene-editing to even more research applications.”
CRISPR RNA, when combined with tracrRNA and Cas9 protein, forms a ribonucleoprotein (RNP) complex that is capable of efficient and effective gene editing. As a part of GenScript’s new synthetic crRNA service, customers will be able to pick from Broad Institute-validated crRNA sequences or custom sequences, that are then synthesized and pre-duplexed to tracrRNA at GenScript. Once received by customers, the crRNA:tracrRNA sequences are complexed with Cas9 protein prior to delivery into cells or embryos, such as mouse and zebrafish, with no synthesis or in vitro transcription required.
"Until now, CRISPR constructs have been DNA-based, carrying a risk of insertional mutagenesis, off-target effects, and toxic delivery into stem cells and primary cells. By working immediately after delivery into the cell, our synthetic CRISPR ribonucleoproteins result in quick DNA editing and rapid cell clearance with fewer off-target risks. GenScript's CRISPR RNAs will expand gene-editing to even more research applications."
Named the 2015 Breakthrough of the Year by the journal Science, the CRISPR/Cas9 technology enables efficient gene-editing with no protein engineering experience necessary. Since its adaptation for mammalian cell editing, the CRISPR/Cas9 gene editing technology has been used for a variety of applications, such as gene knock-out and replacement, and other non-traditional applications including DNA imaging and transcription activation. CRISPR/Cas9 has impacted nearly every area of genetic research.
GenScript’s portfolio of CRISPR products and services include gRNA constructs, in-stock genome-wide and pathway-focused gRNA libraries, mammalian cell-line editing services and microbial gene editing services. For more information on GenScript’s synthetic cRNA services, click here.
About GenScript: GenScript is the world leader in gene synthesis and a peptide, protein, and antibody research partner for fundamental life science research, translational biomedical research, early stage biopharmaceutical development, and synthetic biology. Since its founding in 2002, GenScript has provided services and products to scientists in more than 100 countries worldwide. The company delivers biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, in vitro and in vivo pharmacology and industrial synthetic biology products. For more information, visit http://www.genscript.com/.
TWEET THIS: GenScript Launches New CRISPR Synthetic RNA Service [http://www.genscript.com/] #CRISPR #synbio
Forward-Looking Statement Disclaimer: This press release contains forward-looking statements, including, without limitation, statements related to the earning and sales forecasts. These forward-looking statements are based upon GenScript’s current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: market condition, global stability, new technologies. The forward-looking statements made in this press release speak only as of the date of this press release. GenScript expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GenScript’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
For More Information: